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cause persistent daytime pulmonary hypertension and right ventricular dysfunction.
Objectives: The aims of this study, were to investigate whether OSA by itself without any other
cardiac or lung disease can lead to pulmonary hypertension, and to assess the effect of CPAP ther-
apy on pulmonary artery pressure.
Subjects and methods: The study was performed on 54 OSA patients. All patients were subjected
to thorough history taking including Epworth sleepiness scale and Berlin questionnaire, physical
examinations, calculation of BMI, plain chest X-ray pulmonary function tests, polysomnography
and echocardiography. Ten patients out of 24 patients of OSA with PH have been treated with
CPAP for six months.
Results: Pulmonary hypertension (PH) was present in (44.4%) of OSA patients. There were sig-
niﬁcantly higher PASP and mPAP in severe OSA patients versus non severe OSA patients. There
were signiﬁcant higher BMI, neck circumference, AHI and ODI in OSA patients with PH compared
to OSA patients without PH. Awake SaO2 and minimum SaO2 were signiﬁcantly lower in OSA
patients with PH compared to OSA patients without PH. There were signiﬁcant reduction in both
mPAP and PASP after 6 months of CPAP treatment (p= 0.007, 0.005 respectively).tion index; PH, pulmonary
dex; mPAP, mean pulmonary
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460 A. Shehata ME et al.Conclusion: OSA is associated with pulmonary hypertension, improvement of pulmonary hyper-
tension through controlling OSA by CPAP therapy signiﬁes that OSA plays a crucial role in the
pathogenesis of pulmonary hypertension.
Recommendations: CPAP therapy should be advised to all OSA patients with pulmonary hyper-
tension.
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Obstructive sleep apnea (OSA) is a disorder that is character-
ized by obstructive apneas and hypopneas due to repetitive
collapse of the upper airway during sleep [1].
OSA is associated with repetitive nocturnal arterial O2 desat-
uration and intrathoracic negative pressure swings and an acute
increase in pulmonary artery pressure. Experimentally induced
intermittent hypoxemia in rodents, have been proved to develop
pulmonary vascular remodeling and sustained PH and right
ventricular hypertrophy. Until recently, however, it was unclear
whether episodic nocturnal hypoxemia associated with OSA
was sufﬁcient to cause similar changes in humans [2].
Due to the lack of population-based studies, the true prev-
alence of PH is not known [3]. Many of the studies that dis-
cussed the consequences of untreated OSA are looking for
associations between the prevalence of a cardiovascular conse-
quence at a given time with the severity/presence of OSA [4].
This controversy appears to have been resolved by several
recent studies that have shown pulmonary hypertension in
20–40% of patients with OSA in the absence of other known
cardiopulmonary disorders and reductions in pulmonary ar-
tery pressure in patients with OSA after nocturnal continuous
positive airway pressure (CPAP) treatment [2,5].
Aim of the work
The aims of this study, were to investigate whether OSA by it-
self without any other cardiac or lung disease can lead to pul-
monary hypertension, and to assess the effect of CPAP therapy
on pulmonary artery pressure.
Subjects and methods
This study was carried out at the Sleep-Disordered Breathing
Unit, Chest Medicine Department, Mansoura University Hos-
pitals in the period between June 2009 and September 2011.
The study was performed on 54 OSA patients (29 males and
25 females with age ranged from 30 to 67 years), with >5
and without any heart or lung diseases.
Inclusion criteria
Middle-aged adults with OSA and no other concomitant heart
and lung diseases that may affect pulmonary hemodynamics
enrolled in the study fulﬁlled the following inclusion criteria:
1. Polysomnographic diagnosis of OSA with an apnea–hypo-
pnea index (AHI)> 5 with symptoms suggestive of OSA
(e.g. excessive day time sleepiness, snoring, nocturnal
chocking and witnessed apnea).2. normoxemia and normocapnia based on ABGs.
3. Absence of chronic lung disease, cor pulmonale, myocar-
dial, pericardial, valvular heart disease or arrhythmias
based on clinical and laboratory tests (chest X-ray, electro-
cardiogram, echocardiography).
Exclusion criteria
Other causes of pulmonary hypertension: COPD patients,
chronic thromboembolic disease, connective tissue diseases,
interstitial lung diseases, mitral valve diseases or congestive
heart failure.
Patients subgroups
The selected patients were classiﬁed according to AHI into two
groups:
(I) Severe OSA patient with AHI > 30 [6] (38 cases, 22
males and 16 females with mean age 46.34 ± 6.56)
(II) Non severe OSA patient with AHI 6 30 (16 cases, 7
males and 9 females with mean age 46.13 ± 6.98).And
also were classiﬁed according to pulmonary artery pres-
sure measurement into two groups:(a) OSA patients with pulmonary hypertension (i.e.
mPAP > 25 mmHg) [7].
(b) OSA patients without pulmonary hypertension
(i.e. mPAP 6 25 mmHg).All patients were subjected to
1. Thorough history taking with stress on:Age, chest symptoms,
special habits especially smoking and alcohol intake, cardiac
symptoms, evaluation of excessive day time sleepiness using
the Epworth sleepiness scale [8] and sleep disordered breath-
ing symptoms such as snoring, nocturnal choking, witnessed
apnea at night, and Berlin questionnaire [9].
2. Physical examinations with stress on: Neck circumference.
Body mass index (BMI). Chest and heart examination.
3. Calculation of Body mass index (BMI): The used method
for estimation of the body mass index was the
weight–height index according to the following equation
(BMI = weight (kg)/height2 (m2).
4. Plain chest X-ray.
5. Laboratory tests: Awake arterial blood gases prior to poly-
somnogram session, complete blood picture, Liver function
tests, Serum creatinine, and random blood sugar.
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predicted), forced expiratory volume in the ﬁrst second
(FEV1% of predicted), and FEV1/FVC% ratio were mea-
sured by the standard spirometric technique (Spiro-Jaeger,
Germany), the highest value from at least three spirometric
maneuvers was selected .
7. Polysomnography (PSG): Full night polysomnography
involves the recording of electroencephalography (EEG)
electro-oculography (EOG), submental and anterior tibial
electromyography (EMG), electrocardiography (ECG),
respiratory effort (abdominal and thoracic effort), nasal
and oral airﬂow sensor and oxygen saturation (pulse oxy-
metry). Polysomnography used in this study is a full night
polysomnography (Jaeger Sleep Screen).
8. Echocardiography: To exclude left sided heart diseases (e.g.
mitral valve diseases or congestive heart failure) and for the
assessment of pulmonary artery systolic pressure and mean
pulmonary artery pressure (PASP–mPAP):
(a) PASP measurement: PASP can be reliably deter-
mined from peak TR jet velocity, using the simpli-
ﬁed Bernoulli equation and combining this value with
an estimate of the RA pressure: PASP= 4(V)2 + RA
pressure where V is the peak velocity (in meters per
second) of the tricuspid valve regurgitant jet [10,11].
(b) mPAP: mPAP can be measured by acceleration time
(AT) of the pulmonary velocity ﬂow measured by a
pulsed Doppler of the pulmonary artery in systole,
whereby mean PA pressure = 79  (0.45 · AT) [11,
12]. The same group also found that in patients with
ATs <120 ms, the formula for mean PA pressure is
90 _ (0.62 _ AT) and performed better [13].
9. CPAP therapy: All OSA patients with pulmonary hyperten-
sion were advised to use the CPAP therapy. Only
14 patients agreed to use the CPAP therapy, and follow
up echocardiography was done to them after 6 months
and only 10 patients have completed the study. CPAP
pressure was adjusted according to the following
equation: Auto-CPAP setting: reference pressure (Pre-Table 1 Comparison between severe OSA patients VS non severe O
Epworth scale and Berlin questionnaire, PFT and awake ABGs.
Non-severe OSA (AHI < 30) (n= 16
Age 46.13 ± 6.98
Sex
Male 7 (43.8%)
Female 9 (56.3%)
BMI 26.81 ± 2.07
Neck_cm 38.81 ± 2.20
Epworth_Scale 8.25 ± 1.53
Berlin questionnaire 2.00 ± 0.00
*AHI 15.75 (9.20–30.0)
FEV1 79.22 ± 10.31
FVC 87.86 ± 12.20
FEV1/FVC 90.57 ± 4.44
PaO2 86.46 ± 3.86
PaCO2 37.33 ± 2.84
SaO2 96.63 ± 2.18
* AHI = Apnea–hypopnea index, Median (min – max) and Mann–W
P< 0.05 signiﬁcant.f) = 0.193 · BMI + 0.077 · neck circumference + 0.02 ·
apnea + hypopnea index  0.611 and Pref 4 to Pref
+ 3 cm H2O pressure limits [14].
Some modiﬁcation according to each patient’s comfort and
limitation of side effects was done to the pressure adjustment.
CPAP therapy at least 6 h/day was documented by patients’
bed partner in a sleep diary. The follow up sessions were done
at 7, 30, and 60 days after the initiation of the CPAP therapy
with a phone call by the patient in between sessions and writ-
ten information about any trouble shouting problems during
CPAP use.
Statistical analysis
Data were analyzed using SPSS (Statistical Package for Social
Sciences) version 10. Qualitative data were presented as num-
ber and percent. Comparison between groups was done by the
Chi-square test. Quantitative data were tested for normality by
the Kolmogrov–Smirnov test. Normally distributed data were
presented as mean ± SD. Student’s t-test was used to compare
between two groups. Non parametric variables were presented
as Median (min – max) and the Mann–Whitney test (U test)
was used to compare between two groups. P< 0.05 was con-
sidered to be statistically signiﬁcant.Results
The study included 29 male and 25 female OSA patients; mean
age was 46.28 ± 6.62. The mean of BMI was 30.28 ± 3.72, the
median AHI was 57.55 (9.2 – 132.6) and the median of mPAP
was 25 (10 – 42). Severe OSA with AHI > 30 was present in
(70.3%) and included 38 cases, 22 males and 16 females with
mean age 46.34 ± 6.56. Non severe OSA with AHI < 30
was present in (29.7%) and included 16 cases, 7 males and 9
females with mean age 46.13 ± 6.98. In this study the selected
patients’ spirometric pulmonary function (FEV1, FVC, FEV1/
FVC) of all the studied OSA patients were nearly within theSA patients according to age, sex, anthropometric measurements,
) Severe (AHIP 30) (n= 38) P value
46.34 ± 6.56 0.914
22 (57.9%) 0.341
16 (42.1%)
31.74 ± 3.28 <0.001
43.47 ± 1.96 <0.001
13.34 ± 2.21 <0.001
2.82 ±.39 <0.001
70.25 (35.20–132.60) <0.001
79.84 ± 7.63 0.810
86.44 ± 7.71 0.610
90.29 ± 5.32 0.857
80.51 ± 6.59 <0.001
40.45 ± 6.75 0.082
92.77 ± 3.33 <0.001
hitney U test was used for data with non-parametric distribution,
Table 2 Distribution of pulmonary hypertension among the
studied OSA patients.
No %
OSA with pulmonary hypertension (*mPAP> 25) 24 44.4
OSA without pulmonary hypertension (*mPAP< 25) 30 55.6
* mPAP=Mean pulmonary artery pressure.
462 A. Shehata ME et al.normal range (mean 79.69 ± 8.4, 86.86 ± 9.17, 90.38 ± 5.04
respectively).
There were no signiﬁcant differences in spirometric pul-
monary function tests (FEV1, FVC, FEV1/FVC) between se-
vere OSA patients compared to non severe OSA patients,
and there were no signiﬁcant differences in spirometric pul-
monary function testes as regards FEV1, FVC, and FEV1/
FVC in pulmonary hypertensive patients versus non pulmon-
ary hypertensive patients. There were signiﬁcantly higher
BMI, neck circumference, Epworth scale, Berlin questionnaire
and AHI in severe OSA patients Vs non severe OSA patients
(p=<.001). There were signiﬁcantly lower awake SaO2 and
PaO2 in severe versus non severe OSA patients (p=<.001)
(Table 1).
Pulmonary hypertension (PH) i.e. mPAP > 25 mmHg was
present in 44.4% of OSA patients. (Table 2).
There were signiﬁcantly higher PASP and mPAP in severe
OSA patients versus non severe OSA patients (Table 3).
There were signiﬁcantly more nocturnal oxygen desatura-
tion (signiﬁcant lower basal SaO2, minimum SaO2 and higher
desaturation index p=<.001) in severe OSA patients com-
pared to non severe OSA patients (Table 4).
There were signiﬁcantly higher BMI, neck circumference
and AHI in OSA patients with PH compared to OSA patients
without PH. Awake SaO2 was signiﬁcantly lower in OSA pa-
tients with PH compared to OSA patients without PH
(Table 5).
There was signiﬁcantly higher ODI in OSA patients with
PH versus OSA patients without PH (Table 6).
There were signiﬁcant positive correlations between AHI
and (BMI, ODI, PASP and mPAP) (p< 0.001 for each). Also
there were positive correlations between mPAP and (BMI,Table 4 Comparison between severe OSA patients VS non sev
desaturation.
Non-severe OSA (AHI < 30) (n= 16)
Basal SaO2 93.76 ± 1.52
*ODI 8.47 ± 7.11
Minimum SaO2 85.23 ± 4.96
* ODI = Oxygen desaturation index.
Table 3 Comparison between severe OSA patients VS non severe O
Non-severe OSA (AHI < 30) (n= 16)
PASP 25 (20–49)
mPAP 12 (10–35)
*PASP = Pulmonary artery systolic pressure, mPAP=Mean pulmonary
used for data with non-parametric distribution, P< 0.05 signiﬁcant.ODI). However, there were signiﬁcant negative correlations
between AHI and (PaO2, Basal SaO2 and Minimum SaO2)
(P< 0.001 for each), there were signiﬁcant negative correla-
tions between mPAP and (PaO2 and Minimum SaO2)
(P= 0.005, P< 0.001 respectively) (Table 7).
There were signiﬁcant reductions in both mPAP and PASP
after 6 months of CPAP treatment (p= 0.007 0, 0.005 respec-
tively) with percentage of reduction after 6 months of CPAP
therapy in both mPAP, PASP (26.91% and 23.11% respec-
tively) (Table 8).
Discussion
There has been uncertainty until recently as to whether OSA, is
sufﬁcient to cause persistent daytime PHT and right ventricu-
lar dysfunction. Some studies have concluded that PHT and
right heart disease, if occur in OSA, are always attributable
to other coexisting conditions such as COPD or morbid obes-
ity that resulted in chronic hypoxemia secondary to pulmonary
ventilation–perfusion inequality, alveolar hypoventilation, or
both. However, these studies were conducted among patients
with a mixture of OSA and chronic lung disease, making it dif-
ﬁcult to determine the relative contributions of sleep apnea-re-
lated intermittent hypoxia to PHT and right heart disease [15].
This study was carried out on 54 patients of OSA and no
other concomitant heart or lung diseases that may affect pul-
monary hemodynamics.
Our study revealed that Epworth sleepiness scale (ESS) and
Berlin questionnaire were signiﬁcantly higher in severe OSA
versus non severe OSA (p= .001 for each, Table 1), which sig-
nify that both questionnaire may be a predictor of severity of
OSA Sharma et al. [6] had reported Berlin questionnaire as a
predictor to high risk category of OSA with high sensitivity
(86%) and speciﬁcity (95%). Also, Steven [6] has found a sig-
niﬁcant positive correlation between ESS and AHI and con-
cluded that if ESS was more than 10, sleep related breathing
disorders (SRBDs) should be suspected. They also advised to
assess ESS in SRBDs to rule out or prove OSA and hence
manage it early in the course of the disease. In our study there
were signiﬁcantly higher BMI and neck circumference in severe
OSA patients compared to non severe OSA patients and thereere OSA patients according to parameters of nocturnal O2
Severe (AHIP 30) (n= 38) P value
90.50 ± 2.94 <0.001
64.53 ± 26.17 <0.001
72.74 ± 7.88 <0.001
SA patients according to mPAP and PASP.
Severe (AHIP 30) (n= 38) P value
40.5 (20–50) <0.001
30 (10–42) <0.001
artery pressure. Median (min – max) and Mann–Whitney U test was
Table 5 Comparison between OSA patients with and without
pulmonary hypertension according to age, sex, anthropometric
measurements, Epworth scale and Berlin questionnaire, PFT
and awake ABGs.
Non-PH (n= 30) PH (n= 24) P value
Age 46.43 ± 7.65 46.08 ± 5.21 0.849
Sex
Male 16 (53.3%) 13 (54.2%) 0.951
Female 14 (46.7%) 11 (45.8%)
BMI 28.77 ± 2.71 32.17 ± 4.00 <0.001
Neck_cm 40.93 ± 2.83 43.54 ± 2.43 0.001
*mPAP 13.5 (10–25) 35 (28–42) <0.001
*AHI 33.7 (9.2–107.3) 83.65 (27.9–132.6) <0.001
FEV1 80.29 ± 9.73 78.87 ± 6.53 0.543
FVC 87.49 ± 11.35 86.08 ± 5.50 0.579
FEV1/FVC 89.68 ± 5.37 91.25 ± 4.55 0.260
PaO2 83.64 ± 5.53 80.55 ± 7.26 0.081
PaCO2 38.21 ± 2.87 41.17 ± 8.24 0.072
SaO2 94.93 ± 3.05 92.63 ± 3.67 0.015
* mPAP=Mean pulmonary artery pressure, AHI = Apnea–
hypopnea index. Median (min – max) and Mann–Whitney U test
was used for data with non-parametric distribution, P< 0.05
signiﬁcant.
Table 7 Correlation between AHI and (BMI, PaO2, Basal
CO2, ODI, Min O2, PASP and mPAP).
AHI mPAP
R P r P
BMI 0.685 <0.001 0.433 0.001
PaO2 0.657 <0.001 0.379 0.005
PaCO2 0.264 0.053 0.259 0.058
Basal SaO2 0.727 <0.001
*ODI 0.947 <0.001 0.484 <0.001
Minimum SaO2 0.748 <0.001 0.343 0.011
**PASP 0.600 <0.001
***mPAP 0.546 <0.001
* ODI = Oxygen desaturation index.
** PASP = Pulmonary artery systolic pressure.
*** mPAP=Mean pulmonary artery pressure.
Table 6 Comparison between OSA with and without
pulmonary hypertension according to parameters of nocturnal
O2 desaturation and AHI.
Non-PH (n= 30) PH (n= 24) P value
Basal SaO2 91.81 ± 3.29 91.04 ± 2.56 0.353
*ODI 35.50 ± 31.07 65.83 ± 30.06 0.001
Minimum SaO2 78.91 ± 8.24 73.35 ± 9.42 0.025
* ODI = Oxygen desaturation index.
Pulmonary hypertension in OSA 463were signiﬁcantly higher BMI and neck circumference in
patients with PH patients versus non PH patients. Fishman
et al. [16] concluded that neck circumference greater than
40 cm predicts OSA with sensitivity of 61% and speciﬁcity of93%, regardless of gender. Also, Young and his colleagues re-
ported that neck circumference was the most powerful predic-
tor of OSA among all anthropometric variables studied,
suggesting that the central obesity rather than generalized dis-
tribution of body fat is important for the development of OSA
[17]. Obesity leads to increased amount of fat in the neck which
plays the greatest role in OSA [18]. It is presumed that in-
creased fat deposition in the neck region or adjacent to the
upper airway on the pharyngeal wall can impinge on the pha-
ryngeal lumen and predispose its collapse during sleep. There
is a link between obesity and PH which may be attributed to
the relative deﬁciency of release of adiponectin, which has an
important role in pulmonary vascular inﬂammation suppres-
sion by inhibiting vasoconstricting substances [19].
In this study there was a signiﬁcant positive correlation be-
tween AHI and BMI and also there was a signiﬁcant positive
correlation between mPAP and BMI (Table 7). This was in
agreement with Chaouat et al. [20] who have reported a signif-
icant positive correlation between AHI and BMI, and Arias
et al. [21] who reported high BMI in OSA patients with PH
compared to OSA without PH.
The prevalence of pulmonary hypertension (PH) i.e.
(mPAP > 25 mmHg) [7] in the studied OSA patients was
44.4% (24 out of 54 patients, Table 2), and the median of
mPAP of total group of patients was 25 (10 – 42, Table 1).
OSA alone may cause mild to moderate pH, but coexisting
day time hypoxia is typically required for sustained severe
pH and cor pulmonale [22]. Minai et al. [23] reported that
mild, moderate and even severe PH (i.e. mPAPP 40 mmHg)
can occur in patients with OSA. Moreover, Fletcher et al.
[24] had reported pulmonary hypertension in severe OSA in
the absence of hypoxemic lung disease.
The incidence of PH in OSA patients has been estimated to
be 20–40%. [2,5]. Our result was close to Laks et al. [25] who
reported PH in 42% of OSA patients and Saijkov et al. [26]
who reported PH in 41% of OSA patients. OSA is character-
ized by episodes of apnea and hypopnea during sleep, these
episodes are caused by partial or complete upper airway
obstruction. Episodes of oxygen desaturation cause a transient
increase in pulmonary artery and pulmonary wedge pressures
and permanent PH Marrone and Bonsignore [27] Diurnal
PH was elucidated by the sustained hypoxia which results in
remodeling of the pulmonary vasculature, with intimal smooth
muscle thickening, endothelial perforation, and ﬁbroelastosis
[28].
Daytime hypoxemia has been reported to develop in pa-
tients with OSA [29,30]. In our study OSA patients were with-
out resting hypoxemia but there were signiﬁcantly lower awake
PaO2 and SaO2, in severe OSA patients versus non severe OSA
patients (P< 0.001, for each, Table 1). Meanwhile there was
no signiﬁcant difference in awake PaCO2 in severe OSA versus
non severe OSA patients (Table 1). This was in agreement with
Fanfulla et al. [31] who found signiﬁcantly lower PaO2 and
SaO2 in severe OSA versus non severe OSA and no signiﬁcant
difference in PaCO2 in severe OSA versus non severe OSA. In
this study, there was no signiﬁcant correlation between AHI
and PaCO2 (P= 0.053, Table 7). This was in agreement to
Ayappa et al. [32] who demonstrated no signiﬁcant correlation
between PaCO2 and OSA severity.
In our study there was signiﬁcantly lower awake SaO2 in
the pulmonary hypertensive group versus the non pulmonary
hypertensive group (P= 0.015, Table 5) this was in agreement
Table 8 mPAP and PASP before and after 6 months of CPAP treatment.
N Pre Post P value Percentage of improvement
mPAP 10 35 (28–40) 26 (20–35) 0.007 26.91 (0–37.14)
PASP 10 45 (40–50) 35 (30–42) 0.005 23.11 (11.11–33.33)
*PASP = Pulmonary artery systolic pressure, mPAP=Mean pulmonary artery pressure, Median (min – max) and Mann–Whitney U test was
used for data with non-parametric distribution, P< 0.05 signiﬁcant.
464 A. Shehata ME et al.with most of the other studies [23,21,33] who reported a signif-
icant reduction in daytime SaO2 in the pulmonary hypertensive
group versus teh non pulmonary hypertensive group. Also in
this study both awake PaO2 and PaCO2 were not signiﬁcantly
different between the pulmonary hypertensive group and the
non pulmonary hypertensive group (Table 5). These were in
agreement with Alchanatis et al. [33] and Leech [34].
OSA patients without resting hypoxemia had frequent epi-
sodes of nocturnal desaturation (saw-tooth pattern) that are
more in REM and abolished by CPAP [35]. In this study there
were signiﬁcantly more nocturnal oxygen desaturation (signif-
icant lower basal SaO2, minimum SaO2 and higher desatura-
tion index p=<.001) in severe OSA patients compared to
non severe OSA patients (Table 4). This was as in agreement
with Fanfulla et al. [31]. Also in this study there were signiﬁ-
cant negative correlations between AHI and (PaO2, basal
SaO2 and minimum SaO2) and signiﬁcant positive correlation
between AHI and ODI, Table 7). This was in accordance to
Chaouat et al. [20] who have reported that AHI was signiﬁ-
cantly negatively correlated with (PaO2, basal SaO2 and mini-
mum SaO2).
Nocturnal hypoxemia may be crucial to the development of
pulmonary hypertension [25]. The mechanisms by which alve-
olar hypoxia leads to PH are probably both, pulmonary vaso-
constriction and remodeling of pulmonary vascular bed [36]. It
has been hypothesized that isolated nocturnal hypoxemia
(without signiﬁcant daytime hypoxemia) could lead to pul-
monary hypertension [26]. In this study patients were without
daytime hypoxemia, in the same time the rate of PH encoun-
tered in our OSA patients was high (44.4%), denoting that re-
peated nocturnal hypoxemia alone is the leading factor in the
pathogenesis of PH.
Chronic intermittent hypoxia activates homeostatic mecha-
nisms in the respiratory system that induce changes in gene
expression by mediation of several transcription factors, such
as hypoxia-inducible factors (HIF), both HIF-1a and HIF-
2a, are involved in physiological responses of pulmonary arte-
rioles to chronic intermittent hypoxia, collectively producing
hypertrophy of the pulmonary arteriolar smooth muscle
[31,37].
In this study there were signiﬁcantly higher ODI and signif-
icantly lower minimum SaO2 in the pulmonary hypertensive
group than the non pulmonary hypertensive group (Table 6).
This was in agreement with [25,21]. Also in this study there
was a signiﬁcant positive correlation between mPAP and
ODI, and there was a signiﬁcant negative correlation between
mPAP and PaO2 and minimum SaO2. These were in agreement
with Arias et al. [21].
In this study mPAP and PASP were signiﬁcantly higher in
severe OSA patients versus non severe OSA patients (Table 3).
Also, in our study AHI was signiﬁcantly positive correlated
with mPAP and PASP (Table 7). Leech [34] had concludedthat the severity of OSA is correlated to pulmonary artery
pressure.
These could be explained according to Han et al. [2] who
stated that severe OSA is associated with repetitive nocturnal
arterial O2 desaturation and intrathoracic negative pressure
swings with an acute increase in pulmonary artery pressure
and also intermittent hypoxemia for several hours per day
developed pulmonary vascular remodeling and sustained pul-
monary hypertension.
In our study, 10 out of 24 patients of OSA with PH who
have been treated with CPAP for 6 months, without medical
treatment of PH, have remarkably lowered mPAP (from 35
(28–40) to 26 (20–35), P= 0.007), and also lowered PASP
(from 45 (40–50) to 35 (30–42), with percentage of reduction
in both mPAP and PASP 26.91, 23.11 respectively (Table 8).
This was in agreement with Alchanatis et al. [33] study which
also demonstrated a marked reduction in mPAP after effective
treatment of CPAP therapy for 6 months. Also, in accordance
to Arias et al. [21] who have reported a reduction in PASP in
OSA patients with PH after effective treatment with CPAP
therapy for 6 months. More recently, Oliveira et al. [38] have
reported the beneﬁcial effect of CPAP treatment in reducing
the risk of developing pulmonary hypertension and right ven-
tricular failure in OSA patients. These ﬁndings signify that
there is a causal relationship between OSA and PH.
Conclusion
OSA is associated with pulmonary hypertension which in-
creased with severity. Nocturnal O2 desaturation and increased
BMI are important risk factors in the pathogenesis of pulmon-
ary hypertension in OSA patients. Improvement of pulmonary
hypertension through controlling OSA by CPAP therapy signi-
ﬁes that OSA plays a crucial role in the pathogenesis of pul-
monary hypertension.
Recommendations
CPAP therapy should be advised to all OSA patients with pul-
monary hypertension. All patients with pulmonary hyperten-
sion should be screened for the presence of associated SRBDs.
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